Back to search results

Phase 1b Trial of BMS-986504 and Olaparib for Advanced Solid Tumors with MTAP Loss

This study is testing a combination of two oral medications, BMS-986504 and olaparib, for people with advanced solid tumors that have a specific genetic change called MTAP loss. You might be able to join if you have advanced cancer that hasn't responded to standard treatments or if standard treatments aren't an option for you. The main goal is to see how safe this drug combination is and what side effects it might cause. Researchers will also look at how the drugs move through your body and if they show any signs of shrinking tumors. The study plans to enroll 36 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive the study drugs. It aims to enroll 36 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07382544

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~36 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:MRTX1719Olaparib

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Advanced Cancer
Solid Tumor

Explore related trials

CholangiocarcinomaPancreatic CarcinomaSolid NeoplasmMTAP Gene

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Jordi Rodon Ahnert, MD, PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Jordi Rodon Ahnert, MD, PHD
[email protected]
(713) 792-5603
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count (ANC) ≥ 1500/mm3
Platelets ≥ 100,000/mm3
Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min/1.73 m2 by the Chronic Disease Epidemiology Collaboration equation; estimated creatinine clearance ≥50 mL/min (calculated using institutional standard method).
Adequate hepatic function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Patients with Gilbert's syndrome with total bilirubin ≤ 2.0 × ULN and direct bilirubin within normal limits are permitted; Aspartate aminotransferase/ALT ≤ 3 × institutional ULN or ≤ 5 × ULN for patients with liver metastases.
For patients not receiving therapeutic anticoagulation: international normalized ratio or activated partial thromboplastin time ≤1.5 × ULN. For patients receiving therapeutic anticoagulation: stable anticoagulant regimen. 13. Patients must be able to take PO medications. 14. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result within 72 hours prior to study treatment initiation.
Postmenopausal (no menses in ≥ 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (follicle-stimulating hormone and estradiol in menopausal range and have received whole pelvic radiation therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0